troleandomycin has been researched along with vitamin k 3 in 4 studies
| Studies (troleandomycin) | Trials (troleandomycin) | Recent Studies (post-2010) (troleandomycin) | Studies (vitamin k 3) | Trials (vitamin k 3) | Recent Studies (post-2010) (vitamin k 3) |
|---|---|---|---|---|---|
| 569 | 26 | 23 | 1,316 | 10 | 504 |
| Protein | Taxonomy | troleandomycin (IC50) | vitamin k 3 (IC50) |
|---|---|---|---|
| perilipin-5 | Homo sapiens (human) | 9.468 | |
| perilipin-1 | Homo sapiens (human) | 7.895 | |
| 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform a | Homo sapiens (human) | 8.6815 | |
| Aldehyde oxidase 1 | Mus musculus (house mouse) | 0.15 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 7.96 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 7.96 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 0.8925 | |
| Protein kinase C alpha type | Homo sapiens (human) | 2.2 | |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | 3.02 | |
| Protein-glutamine gamma-glutamyltransferase 2 | Homo sapiens (human) | 2.2 | |
| M-phase inducer phosphatase 1 | Homo sapiens (human) | 4.55 | |
| M-phase inducer phosphatase 2 | Homo sapiens (human) | 3.16 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 2.2 | |
| Aldehyde oxidase 1 | Oryctolagus cuniculus (rabbit) | 2 | |
| Aldehyde oxidase | Homo sapiens (human) | 0.2 | |
| Receptor-type tyrosine-protein phosphatase eta | Homo sapiens (human) | 2.2 | |
| Thiosulfate sulfurtransferase | Homo sapiens (human) | 1 | |
| Receptor protein-tyrosine kinase | Homo sapiens (human) | 2.2 | |
| 60 kDa chaperonin | Escherichia coli | 5.75 | |
| Aldehyde oxidase 1 | Macaca fascicularis (crab-eating macaque) | 0.11 | |
| 10 kDa chaperonin | Escherichia coli | 5.75 | |
| Aldehyde oxidase 1 | Rattus norvegicus (Norway rat) | 0.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
4 other study(ies) available for troleandomycin and vitamin k 3
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |